eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Glenwood GmbH

Riedener Weg 23, 82319 Starnberg, Germany
Telephone: +49 8151 998790
Fax: +49 8151 9987910
Medical Information e-mail: info@glenwood.de

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 25/04/2011
SPC Myotonine 10 mg (Bethanechol Chloride)


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Myotonine Tablets 10mg


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 10mg tablet weighs 400mg; total active ingredient 10mg bethanechol chloride USP.


Go to top of the page
3. PHARMACEUTICAL FORM

Each 10mg tablet is white, flat with bevelled edge and with a single score and embossed “MYO10”.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Urinary retention -acute postoperative, postpartum and neurogenic.

Reflux oesophagitis.


Go to top of the page
4.2 Posology and method of administration

Administration orally by tablets.

Adults: 10 mg - 25mg 3-4 times daily. Taken ½ hr before food. Occasionally it may be felt necessary to initiate therapy with a 50mg dose.

Children: The experience with children is limited; therefore no recommended dose is given.

Elderly: Adult dosage administered with caution.


Go to top of the page
4.3 Contraindications

Intestinal or urinary obstruction, recent myocardial infarction, recent intestinal anastomosis.


Go to top of the page
4.4 Special warnings and precautions for use

A severe cholinergic reaction is likely to occur if Bethanechol Chloride is administered IV or IM. This reaction has also rarely occurred in cases of hypersensitivity or overdose.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

Pharmacological interactions may occur with the following when bethanechol is administered. Quinidine and procainamide which may antagonise cholinergic effects, cholinergic drugs which may have an additive effect, particularly cholinesterase inhibitors. When administered to patients receiving ganglionic blocking compounds, a critical fall in blood pressure may occur preceded by severe abdominal symptoms.


Go to top of the page
4.6 Pregnancy and lactation

Should not be used during pregnancy or lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

In some cases the ability to drive and operate machinery may be impaired.


Go to top of the page
4.8 Undesirable effects

Nausea, vomiting, sweating and intestinal colic.


Go to top of the page
4.9 Overdose

Symptoms: Include nausea, salivation, lachrymation, eructation, involuntary defecation and urination, transient dyspnoea, palpitation, bradycardia and peripheral vasodilation leading to hypertension, transient heart block and a feeling of constriction under the sternum.

Emergency Procedure: The stomach should be emptied by aspiration and lavage.

Give atropine sulphate 1-2mg intravenously, intramuscularly or subcutaneously to control muscarinic effects. This dose may be repeated every 2-4 hours as necessary. Supportive treatment includes intravenous administration of diazepam 5-10mg:muscle twitching may be controlled by small doses of tubocararine (together with assisted respiration): oxygen may be required.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Bethanechol is a synthetic choline ester of carbamic acid which possesses a significant acetylcholine-like activity. It is active after oral administration. As a consequence of the very slow hydrolysation by acetylcholinesterase, bethanechol has a prolonged action as has been demonstrated on the urinary tract. The onset of action after oral administration of bethanechol chloride occurs within one hour.

The major pharmacological effects of bethanechol result from interaction of the drug with muscarinic receptor sites of smooth muscles, especially those of the urinary bladder and gastrointestinal tract. In addition, minor but important nicotinic effects have been noted.


Go to top of the page
5.2 Pharmacokinetic properties

In usual therapeutic doses, bethanechol does not cross the blood brain barrier. Studies addressing pharmacokinetic- pharmacodynamic are not available.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Calcium sulphate dihydrate BP;

Maize starch BP;

Purified talc BP


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

None. Keep out of reach of children.


Go to top of the page
6.5 Nature and contents of container

The container consists of blister strips of PVC/ aluminium foil packed in boxes. Each container holds 100 tablets.


Go to top of the page
6.6 Special precautions for disposal and other handling

None


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Glenwood GmbH

Riedener Weg 23

82319 Starnberg

Germany


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 22824/0003


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

4th December 1973/ 9th May 1996


Go to top of the page
10. DATE OF REVISION OF THE TEXT

25/10/2010



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/10891/SPC/


Active Ingredients/Generics

 
   bethanechol chloride